Category: by institution

Harvard diabetes researcher retracts third paper

A prominent diabetes researcher based at Harvard Medical School has retracted a third paper, citing manipulation of multiple figures.

Late last year, Carl Ronald Kahn—also chief academic officer at Joslin Diabetes Center—retracted two papers for similar reasons. In November, Kahn pulled a 2005 paper from The Journal of Clinical Investigation (JCI) and a month later, he retracted a 2003 paper from The Journal of Biological Chemistry (JBC), both times citing duplications that the authors said were introduced while assembling the figures.

Last month, Kahn retracted his third paper, also published in JBC in 2003, because the authors omitted data when constructing the images. Still, the authors remain confident in their findings, given that data from other labs “have confirmed and extended the conclusions of the manuscript.”

Here’s the retraction notice: Continue reading Harvard diabetes researcher retracts third paper

Two researchers guilty of misconduct, says university investigation

Suchitra Sumitran-Holgersson

A Swedish university has concluded that two professors studying tissue engineering are guilty of misconduct in two published papers, including a 2012 study in The Lancet.

The two researchers are  Suchitra Sumitran-Holgersson and Michael Olausson, both based at the University of Gothenburg. The university investigation — launched after several of Holgersson’s papers were questioned on PubPeer — has concluded that the researchers didn’t follow proper ethical procedures in the two papers.

Here’s a statement from a university spokesperson:

Continue reading Two researchers guilty of misconduct, says university investigation

Huh? Cancer paper gets retracted because of its correction

Here’s a rather odd case: When readers raised issues about some of the images in a 2008 cancer paper, the authors issued a correction last year. But when readers asked additional questions about the corrected images, the authors decided to retract the paper entirely, along with its correction.

Both the original and corrected versions were questioned on PubPeer.

Here’s the retraction notice for the 2008 article “PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2,” published in Oncogene, which includes a link to the July 2016 correction: Continue reading Huh? Cancer paper gets retracted because of its correction

Unexplained abnormalities in stem cells prompt Columbia researchers to pull diabetes paper

Researchers at Columbia University have retracted a 2013 paper in The Journal of Clinical Investigation, after uncovering abnormalities in the stem cell lines that undermined the conclusions in the paper.

Last year, corresponding author Dieter Egli discovered he could not reproduce key data in the 2013 paper because almost all the cell lines first author Haiqing Hua used contained abnormalities, casting doubt on the overall findings. When Egli reached out to Hua for answers, Hua could not explain the abnormalities. As a result, Hua and Egli agreed the paper should be retracted.

Since some of the details of how the paper ended up relying on abnormal cells remain unclear, the university confirmed to us that it is investigating the matter.

Here’s the retraction notice for “iPSC-derived β cells model diabetes due to glucokinase deficiency,” cited 42 times: Continue reading Unexplained abnormalities in stem cells prompt Columbia researchers to pull diabetes paper

High-profile book on North Korea earns 52 corrections

The author of a high-profile book about the history of North Korea is issuing 52 corrections to the next edition, scheduled to appear this spring. The changes follow heavy criticism of the book, alleging it contained material not supported by the list of references.

Last month, author Charles Armstrong, a professor at Columbia University, announced on his website that he was issuing the changes after reviewing the book in detail, especially the footnotes. He writes:

Continue reading High-profile book on North Korea earns 52 corrections

Prominent Harvard researcher issues second retraction, again citing duplication

The former president of the Joslin Diabetes Center has withdrawn a second article within a month of his first, and issued extensive corrections to another paper in the same journal, all due to figure errors.

In November, we reported that Carl Ronald Kahn — also affiliated with Harvard Medical School — had pulled a highly cited 2005 paper from The Journal of Clinical Investigation because of image duplication issues, which Kahn told us were introduced during figure assembly. This December, Kahn retracted a 2003 paper published in The Journal of Biological Chemistry (JBC)—again due to duplication issues that the authors believe “were inadvertently introduced during figure assembly.”

Here’s the retraction notice for “Bi-directional regulation of brown fat adipogenesis by the insulin receptor,” cited 46 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters:

Continue reading Prominent Harvard researcher issues second retraction, again citing duplication

A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Last March, a PhD student at Harvard filed a misconduct allegation against his mentor, a prominent stem cell researcher. Three months later, he was taken from his home by police in the middle of the night for a forced psychiatric evaluation.

How did this happen? Continue reading A Harvard whistleblower was subjected to a forced mental exam. Here’s why.

Karolinska requests retraction of 2014 Macchiarini paper

Paolo Macchiarini

It has been a tough couple of years for surgeon Paolo Macchiarini, once lauded for pioneering a groundbreaking procedure to transplant tracheas.

After a series of documentaries prompted his former employer, Karolinska Institutet (KI), to reopen a misconduct investigation against him, KI has today released one verdict regarding a 2014 Nature Communications paper: guilty.

KI said it is contacting the journal to request a retraction of the paper, which has already been flagged with an expression of concern.

Here’s more from a release from the institution: Continue reading Karolinska requests retraction of 2014 Macchiarini paper

Columbia has settled a fraud case for $9.5M. Here’s why that’s important.

John Thomas
John Thomas

This summer, Columbia University signed a settlement agreement with the U.S. government over a case filed under the False Claims Act (FCA), which enables whistleblowers to sue institutions on behalf of the government. Although this may seem like one of the many legal issues facing academic science recently, this case merits a closer look, says John R. Thomas, Jr., an attorney with Gentry Locke who represents whistleblowers in a variety of FCA cases – including a potentially landmark case against Duke University that we covered for Science. Thomas – who also authored a three-part Retraction Watch primer on how to file an FCA suit (“So You Want to Be a Whistleblower?” Part One, Part Two, Part Three) – tells us what we need to know about this latest FCA verdict.

As readers of Retraction Watch are unfortunately well aware, dishonesty in research comes in many forms. While we often focus on dishonesty in research itself, scientists and institutions may also defraud the government through a variety of administrative avenues, such as effort reporting (accounting for researcher time), improper cost accounting, and inflated facilities and administrative (F&A) costs.

We saw an example of this in July, when Continue reading Columbia has settled a fraud case for $9.5M. Here’s why that’s important.

Scientists investigated for misconduct lose appeal in suit against Harvard. Lawyers explain what it means.

Paul S. Thaler
Paul S. Thaler
Richard Goldstein
Richard Goldstein

Retraction Watch readers may recall the case of Piero Anversa and Annarosa Leri, both formerly of Harvard and the Brigham & Women’s Hospital in Boston. The pair — which has had their work subjected to a retraction, expression of concern, and correction — sued their former employers in 2014 for costing them job offers after the institutions notified journals, triggering notices. A judge dismissed the case a year ago, saying that Anversa and Leri had to try other administrative remedies before bringing suit.

But Anversa and Leri appealed, and last week, a court denied that appeal. (See the judge’s decision — which begins by quoting Ecclesiastes and includes the delicious word “gallimaufry” — here.) We spoke by email to two attorneys — Richard Goldstein, who represented the scientist in Bois v. HHS, the first case to overturn a funding ban by the Office of Research Integrity (ORI), and Paul Thaler, who has represented scientists involved in misconduct proceedings for more than 25 years — about the case, and what it could mean for similar lawsuits.

Retraction Watch: The decision seems to stop Anversa and Leri from continuing their suit against Harvard and the Brigham, but also acknowledges some of the scientists’ concerns as legitimate. How would you summarize the findings and their implications? Continue reading Scientists investigated for misconduct lose appeal in suit against Harvard. Lawyers explain what it means.